Luly Jay R. 4

What Happened

• Luly Jay R., President, CEO and Director of Enanta Pharmaceuticals (ENTA), received 20,000 shares of common stock on February 12, 2026 from vested equity awards (4,800 PSUs and 15,200 rTSRUs) issued at $0.00. To cover withholding taxes on the settlement, 6,155 shares were automatically forfeited at $14.25 per share, valued at $87,709. Net shares received by the insider from this settlement: 13,845.

Key Details

• Transaction dates: awards vested and shares issued on 2026-02-12; filing submitted 2026-02-13 (timely).
• Transaction types: A = award/grant (4,800 and 15,200 shares issued at $0.00); F = shares forfeited to cover tax withholding (6,155 shares disposed at $14.25).
• Value of shares withheld for taxes: 6,155 × $14.25 = $87,709.
• Shares owned after transaction: not specified in the filing.
• Footnotes: PSUs vested based on two-year R&D milestones (calendar 2024–2025); rTSRU vested based on relative total shareholder return versus Nasdaq Biotech Index over two-year periods; forfeiture of 6,155 shares was an automatic tax-withholding action.

Context

• These were performance-based awards that vested and were settled in stock (not an open-market purchase or sale by the insider). The withheld shares are a routine tax-withholding method and are reported as a disposal (F) for reporting purposes, not a cash sale by the insider.